|
Stock-Based Compensation
|
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2013
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-Based Compensation |
The Company recognized stock-based compensation on all employee and non-employee awards as follows:
The Company granted -0- and 35,000 stock options, with a weighted-average grant date fair value of -0- and $3.41 per share, during the three and nine months ended September 30, 2013, respectively. The Company granted -0- and 100,000 stock options, with a weighted-average grant date fair value of $0 and $1.03 per share, during the three and nine months ended September 30, 2012, respectively. During the nine months ended September 30, 2013, 50,533 stock options previously granted have vested, 56,050 stock options were forfeited and 31,533 included in outstanding stock options were exercised. Included in the results for the September 30, 2013 quarter is a liability and expense in the amount of $1,487,801 relating to probable awards under the Company’s 2012 Equity Incentive Plan (“2012 Plan”) pursuant to the Company’s long term performance based incentive programs for certain members of management and independent directors that were triggered by the Probiotic ECC. The liability and expense amount represents the grant date fair value of the 422,359 shares expected to be awarded under the 2012 Plan. See Note 8 – Subsequent Events. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||